The Food and Drug Administration inspected OneBlood, Inc. in Port Charlotte on April 9, focusing on blood and blood products, according to data posted on the FDA’s website.
The final assessment found that OneBlood, Inc. was not required to take any action to amend its operational management.
The FDA performs regular facility inspections nationwide to assess whether worksites and their products comply with laws and regulations intended to support public health. Inspection outcomes are made public.
The agency states on its website that it primarily oversees the safety and quality of human and animal drugs, biological products, medical devices, and tobacco products.
Information for this article was sourced from the U.S. Food and Drug Administration. The original data is available here.
